Samsung Bioepis Set To Join High-Concentration Humira Party In Canada
Health Canada Approval Follows Celltrion, JAMP Launches
Samsung Bioepis has confirmed launch plans for its citrate-free, high-concentration Hadlima (adalimumab) biosimilar after it was waved through the Canadian healthcare regulator.
You may also be interested in...
Organon: ‘Those $4bn-$5bn Biologics – That’s A Nice Place To Play In Biosimilars’
Joe Azzinaro, Organon’s global commercial leader for biosimilars, sat down to talk with Generics Bulletin about its commercialization expertise and investments for the future.
Alvotech And Teva File US Stelara Rival Ahead Of 2023 Expiry
Alvotech and marketing partner Teva have confirmed that their AVT04 proposed ustekinumab biosimilar rival to Stelara has been filed with the US FDA, ahead of a key patent expiry later this year.
Organon Launches Two Biosimilars In Canada As Sales Slide
Organon has launched its Ontruzant trastuzumab biosimilar version of Herceptin and its Aybintio bevacizumab rival to Avastin in Canada. The launches come shortly after the firm revealed biosimilars sales that were slightly down in Q3.